Abstract
This study compared the efficacy and toxicity of Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil (5-FU) in patients of recurrent squamous cell carcinoma of head and neck (SCCHN) treated with palliative intent. Patients with recurrent SCCHN not amenable to curative treatment were randomly assigned to Gefitinib, Methotrexate or Methotrexate plus 5-FU arm. The primary end point was overall survival. Secondary end points of interest were objective response rate, toxicity and quality of life. Total 117 patients were analyzed. Median overall survival and objective response rates were 8.8 months, 7.8 months and 8.1 months and 7.7%, 5.0% and 7.9% in Gefitinib, Methotrexate and Methotrexate plus 5-FU arms respectively with no statistically significant difference between 3 arms. Gefitinib had different toxicity profile compared with other arms. Majority of toxicities were Grade 1 or Grade 2. Gefitinib had significant improvement in quality of life during initial months over Methotrexate. There was no suggestion that Gefitinib significantly prolonged overall survival compared with Methotrexate and Methotrexate plus 5-FU. However, improved Quality of Life with manageable toxicities was observed.
References
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A ForastiereS K Williamson
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C JacobsL Schacter
Dec 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G P BrowmanM N Levine
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchornagelM Clavel
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F CellaJ Brannon
Nov 1, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Muhyi Al-Sarraf
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·K Kian AngLuka Milas
Jul 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B BrocksteinE E Vokes
Jul 12, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Masayuki ShirakiHiroyoshi Hiratsuka
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara BurtnessUNKNOWN Eastern Cooperative Oncology Group
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ezra E W CohenEverett E Vokes
Feb 24, 2006·British Journal of Cancer·A M KirbyK J Harrington
Jun 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Dimitrios Colevas
Jun 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shailaja Kalyankrishna, Jennifer R Grandis
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine H ChungFred R Hirsch
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Simon W StewartEverett E Vokes
Oct 16, 2009·Expert Review of Anticancer Therapy·Fernando RiveraLourdes Gutiérrez-Sanz
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B Vermorken, P Specenier
Jul 12, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jacques TortochauxJean Bourhis
Aug 25, 2011·Drugs·Bruce E Brockstein
Jan 19, 2012·Current Treatment Options in Oncology·Katharine A R Price, Ezra E Cohen
Citations
Aug 25, 2015·Clinical Oral Investigations·Stefan HartmannUrs D A Müller-Richter
Jan 18, 2017·Nanomedicine·Minhui ZhuHongliang Zheng
Nov 2, 2018·JAMA Oncology·Lillian L SiuJérôme Fayette
Mar 21, 2019·Current Opinion in Oncology·Esma Saada-BouzidJoël Guigay
Jan 7, 2020·Head & Neck·Janneke C HamCarla M L van Herpen
Jan 5, 2020·Expert Review of Anticancer Therapy·Akhil RajendraKumar Prabhash
May 20, 2020·International Journal of Molecular Sciences·Przemysław KoźmińskiEwa Gniazdowska
Jun 27, 2019·Current Treatment Options in Oncology·Joël GuigayCécile Michel
Jul 10, 2020·Journal for Immunotherapy of Cancer·Byoung Chul ChoNicolas Penel
Dec 24, 2018·Medicine·Yong XinLongzhen Zhang
May 26, 2017·Frontiers in Oncology·Athanassios ArgirisLisa Licitra
Sep 22, 2018·Oncotarget·Hunter John PiegolsVilma Yuzbasiyan-Gurkan
Jan 27, 2019·Oncotarget·Christian BorelPierre Coliat
Dec 27, 2018·British Journal of Cancer·Zhipeng LiHancai Dan
Jun 27, 2019·Journal of Oncology·Xiaoxia TangLong Chen
Feb 26, 2021·Immunotherapy·Lingrong TangGuang Li
Jul 3, 2021·Biomolecules·Jingjing ShaTakahiro Kanno
Jul 16, 2021·Curēus·Razia IrshadAnusha Hassan